Showing metabocard for N-Acetylvaline (MMDBc0000460)
| Record Information | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Version | 1.0 | ||||||||||||||||||||||||||||
| Status | Detected and Quantified | ||||||||||||||||||||||||||||
| Creation Date | 2020-12-10 18:38:16 UTC | ||||||||||||||||||||||||||||
| Update Date | 2024-04-30 19:32:29 UTC | ||||||||||||||||||||||||||||
| Metabolite ID | MMDBc0000460 | ||||||||||||||||||||||||||||
| Metabolite Identification | |||||||||||||||||||||||||||||
| Common Name | N-Acetylvaline | ||||||||||||||||||||||||||||
| Description | N-Acetyl-L-valine or N-Acetylvaline, belongs to the class of organic compounds known as N-acyl-alpha amino acids. N-acyl-alpha amino acids are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. N-Acetylvaline can also be classified as an alpha amino acid or a derivatized alpha amino acid. Technically, N-Acetylvaline is a biologically available N-terminal capped form of the proteinogenic alpha amino acid L-valine. N-acetyl amino acids can be produced either via direct synthesis of specific N-acetyltransferases or via the proteolytic degradation of N-acetylated proteins by specific hydrolases. N-terminal acetylation of proteins is a widespread and highly conserved process in eukaryotes that is involved in protection and stability of proteins (PMID: 16465618 ). About 85% of all human proteins and 68% of all yeast proteins are acetylated at their N-terminus (PMID: 21750686 ). Several proteins from prokaryotes and archaea are also modified by N-terminal acetylation. The majority of eukaryotic N-terminal-acetylation reactions occur through N-acetyltransferase enzymes or NAT’s (PMID: 30054468 ). These enzymes consist of three main oligomeric complexes NatA, NatB, and NatC, which are composed of at least a unique catalytic subunit and one unique ribosomal anchor. The substrate specificities of different NAT enzymes are mainly determined by the identities of the first two N-terminal residues of the target protein. The human NatA complex co-translationally acetylates N-termini that bear a small amino acid (A, S, T, C, and occasionally V and G) (PMID: 30054468 ). NatA also exists in a monomeric state and can post-translationally acetylate acidic N-termini residues (D-, E-). NatB and NatC acetylate N-terminal methionine with further specificity determined by the identity of the second amino acid. N-acetylated amino acids, such as N-acetylvaline can be released by an N-acylpeptide hydrolase from peptides generated by proteolytic degradation (PMID: 16465618 ). In addition to the NAT enzymes and protein-based acetylation, N-acetylation of free valine can also occur. Excessive amounts N-acetyl amino acids including N-acetylvaline(as well as N-acetylglycine, N-acetylserine, N-acetylmethionine, N-acetylglutamate, N-acetylalanine, N-acetylleucine and smaller amounts of N-acetylglutamine, N-acetylisoleucine, and N-acetylthreonine) can be detected in the urine with individuals with acylase I deficiency, a genetic disorder (PMID: 16465618 ). Aminoacylase I is a soluble homodimeric zinc binding enzyme that catalyzes the formation of free aliphatic amino acids from N-acetylated precursors. In humans, Aminoacylase I is encoded by the aminoacylase 1 gene (ACY1) on chromosome 3p21 that consists of 15 exons (OMIM 609924 ). Individuals with aminoacylase I deficiency will experience convulsions, hearing loss and difficulty feeding (PMID: 16465618 ). ACY1 can also catalyze the reverse reaction, the synthesis of acetylated amino acids. Many N-acetylamino acids, including N-acetylthreonine, are classified as uremic toxins if present in high abundance in the serum or plasma (PMID: 26317986 ; PMID: 20613759 ). Uremic toxins are a diverse group of endogenously produced molecules that, if not properly cleared or eliminated by the kidneys, can cause kidney damage, cardiovascular disease and neurological deficits (PMID: 18287557 ). | Read more...||||||||||||||||||||||||||||
| Structure |  | ||||||||||||||||||||||||||||
| Synonyms |
| ||||||||||||||||||||||||||||
| Molecular Formula | C7H13NO3 | ||||||||||||||||||||||||||||
| Average Mass | 159.185 | ||||||||||||||||||||||||||||
| Monoisotopic Mass | 159.089543283 | ||||||||||||||||||||||||||||
| IUPAC Name | (2S)-2-acetamido-3-methylbutanoic acid | ||||||||||||||||||||||||||||
| Traditional Name | L-valine, N-acetyl- | ||||||||||||||||||||||||||||
| CAS Registry Number | Not Available | ||||||||||||||||||||||||||||
| SMILES | CC(C)[C@H](NC(C)=O)C(O)=O | ||||||||||||||||||||||||||||
| InChI Identifier | InChI=1S/C7H13NO3/c1-4(2)6(7(10)11)8-5(3)9/h4,6H,1-3H3,(H,8,9)(H,10,11)/t6-/m0/s1 | ||||||||||||||||||||||||||||
| InChI Key | IHYJTAOFMMMOPX-LURJTMIESA-N | ||||||||||||||||||||||||||||
| Chemical Taxonomy | |||||||||||||||||||||||||||||
| Functional Ontology | |||||||||||||||||||||||||||||
| Physical Properties | |||||||||||||||||||||||||||||
| Spectra | |||||||||||||||||||||||||||||
| Biological Properties | |||||||||||||||||||||||||||||
| Human Proteins and Enzymes | |||||||||||||||||||||||||||||
| Human Pathways | |||||||||||||||||||||||||||||
| Metabolic Reactions | |||||||||||||||||||||||||||||
| Health Effects and Bioactivity | |||||||||||||||||||||||||||||
| Microbial Sources | |||||||||||||||||||||||||||||
| Exposure Sources | |||||||||||||||||||||||||||||
| Host Biospecimen and Location | |||||||||||||||||||||||||||||
| External Links | |||||||||||||||||||||||||||||
| References | |||||||||||||||||||||||||||||
